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Abstract Macrophages are one of the most important immune cell pop-
ulations that can be found inside solid tumours. For a long time, it was
thought that these cells have an anti-tumour role, but relatively recent re-
search has shown that they can have both anti-tumour and pro-tumour roles
as determined by their phenotypes. Due to the heterogeneity and plasticity
of macrophage population, with cells changing their phenotypes in response
to the tumour microenvironment, it is difficult to fully understand their role
inside the solid tumours. Here we consider a mathematical modelling and com-
putational approach to investigate the change in macrophages phenotypes (ei-
ther determined by the tumour itself, or by external interventions) on overall
tumour growth/control/decay. To this end we consider two simple models: one
focusing on two extreme phenotypes (the M1 anti-tumour cells, and the M2
pro-tumour cells), and one considering a macrophage population structured
by a continuous phenotype variable. We investigate their asymptotic dynamics
(through steady-state analysis), as well as their transient behaviours (through
numerical simulations). We show that while a re-polarisation of the phenotype
of macrophages, as considered by many recent experimental studies, can lead
to tumour control, for tumour elimination it is required that macrophages are
fully functional (i.e., the rate at which they kill tumour cells is high). We
also show that a mixed macrophage’s phenotype can keep the tumour under
control in a state of dormancy. Moreover, an increase in this mixed pheno-
type can cause a delay in tumour reduction (accompanied by a larger tumour
reduction), as well as a delay in tumour relapse.
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1 Introduction
More and more experimental studies emphasise the importance of tumour-
macrophage interactions on the progression of malignant tumours [2,11,46,47,
49,70]. One reason is that macrophages can represent between 5-40% of solid
tumour mass [64,66]. For years it was thought that macrophages, as immune
cells, have an anti-tumour role [19,20]. However, experimental studies over
the last 20-30 years have shown that macrophages are a very heterogeneous
and plastic cell population, which can eliminate tumours as well as help them
grow larger. The heterogeneity of macrophages, with phenotypes varying from
the anti-tumour classically-activated M1 cells to the pro-tumour alternatively-
activated M2 cells (see also Fig.1), makes it difficult to understand and control
their roles in tumour progression, especially when macrophages express mark-

























Fig. 1 The two extreme macrophage phenotypes are represented by the M1 and M2 cells.
However, between them there is a continuous range of phenotypes. As tumour progresses, it
induces macrophages re-polarisation from mainly a M1 phenotype towards a M2 phenotype.
In this study we focus on breast cancer (i.e., the 4T1 murine breast cancer
cell line), which is associated with very large numbers of macrophage infil-
trates that can form up to 40% of tumour mass [14,45,66]. Many experimental
studies on breast cancers have shown a M1→M2 polarisation of macrophages
co-cultured with 4T1 cells [41,46,64,71]. The M2 cells were also associated
with a fast tumour proliferation [64]. The poor prognosis of tumours with
large macrophages infiltrates, combined with the plasticity of macrophages
(i.e., these cells can change their phenotype in response to the environment
they are in) lead researchers to suggest a M2→M1 macrophage re-polarisation
as a way of treating cancers [24,32,49]. In fact, recent experimental studies
have shown that the re-polarisation of M2 macrophages towards an M1-like
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phenotype (e.g., by antibody targeting as in [25]) can inhibit breast cancer
progression. Moreover, there are studies suggesting that the 4T1 breast cancer
cells, which secrete extracellular vesicles up-taken by macrophages, can in fact
prime the tumour-associated macrophages towards an M1-like phenotype [43].
This result could probably be explained by the mixed M1/M2 phenotypes
of macrophages infiltrates in some solid tumours [45]. In fact, these mixed
M1/M2 phenotypes are quite common in various cancers: from breast can-
cers [45], to prostate cancers [60], ovarian cancers [59], pancreatic cancers [35],
lung cancers [63], skin cancers [3]. The differentiation of these macrophages
with mixed phenotypes, which express markers corresponding to the M1 phe-
notype (e.g., HLA-DRhi, CD11, CD80) as well as markers corresponding to
the M2 phenotype (e.g., HLA-DRlo, CD206, CD163), is the result of various
tumour-derived factors [35], and allows the macrophages to adjust to their en-
vironment. However, despite the phenotypic characterisation of macrophage
populations infiltrating various tumours (sometimes using markers that might
not always be perfect indicators of the extent of cell polarisation [59]), the role
of these mixed-phenotype macrophages on tumour progression is still not fully
understood.
Here, we consider a mathematical approach to investigate the effect of in-
jecting a number of cancer cells into a mouse (as done in various experimental
setups [28]; see also Fig. 2), which leads to the accumulation of macrophages
with different phenotypes inside the tumour microenvironment. The mathe-
matical studies published in the literature focus mainly on the effect of the two
extreme types of macrophages, M1 and M2 cells, on tumour evolution; see [4,
15,16,39,40,44,52,57]. However, as mentioned above, the tumour-associated
macrophages have a continuous range of phenotypes, with many cells express-
ing markers characteristics of both M1 and M2 phenotypes [2,45]. This as-
pect, which is missing from the mathematical literature, will be addressed
in this study. In particular, we will use the mathematical models derived in
this study to better understand the impact that the number of immune cells
with mixed phenotypes vs. immune cells with single phenotypes could have on
the growth/control/elimination of tumour cells. We will also investigate the
impact of changes in macrophages polarisation/re-polarisation rates, either in-
duced by normal tumour progression or by external treatment [32,49], as well
as changes in the rates at which M1-like macrophages eliminate tumours [34],
on the overall growth/control/elimination of these tumour cells. In particu-
lar, we will show that tumour control (dormancy) can occur in the presence of
macrophages with mixed phenotypes that have medium anti-tumour activities.
We acknowledge that the tumour microenvironment contains multiple types
of immune cells (e.g., CD8+ and CD4+ T cells, B cells, granulocytes [14]) that
interact directly or indirectly with the macrophages, and thus can influence
their dynamics. However, to keep the mathematical model as simple as possi-
ble, and to identify the main mechanisms behind tumour growth/control/decay,
here we focus only on the macrophage population.
We start in Section 2 with the description of two mathematical models
for tumour-macrophages interactions: a model that focuses on the two dis-
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crete extreme macrophage phenotypes (M1 and M2), and a model that con-
siders the phenotype as a continuum variable which induces a structure in the
macrophage population. In Section 3 we investigate the transient and asymp-
totic dynamics of these two models by focusing on both numerical simulations
and stability analysis of steady states. We summarise and further discuss the
results in Section 4.
2 Model description
To develop the mathematical model for tumour-macrophage interactions, we
use a step-by-step approach. In subsection 2.1 we focus on a simple model for
the dynamics of the two extreme types of macrophages, M1 and M2 cells, and
their interactions with the tumour cells inside the tumour micro-environment.
Then, in subsection 2.2 we combine the two equations for the M1 and M2 pop-
ulations into one equation for the macrophages structured by the phenotype
variable m ∈ [0, Lm] (with m = 0 describing the pure M1 cells, and m = Lm
describing the pure M2 cells). Both mathematical models describe a hypo-
thetical experimental protocol summarised in Fig. 2 (which follows the steps
of many experimental protocols [5]), where a certain number of tumour cells
are injected into a mice and a few days later we start to investigate the tumour-
immune dynamics. It should be mentioned that the subcutaneous injection of
cancer cells into the mice (see classical experimental murine protocols [28,
53]) leads to an inflammatory microenvironment which attracts (within 48
hours [8]) the M1 macrophages. Thus, for both models below, we assume that










evolution of tumour cells
t=0
Fig. 2 A hypothetical experiment investigated in this study. We assume that a number
of breast tumour cells have been inoculated into the system, and 2 days later (when the
tumour has started growing and has attracted the M1 pro-inflammatory macrophages) we
start investigating the dynamics of tumour-immune interactions.
2.1 Discrete phenotype macrophage populations
For simplicity, we start by assuming that the macrophage population is rep-
resented by the 2 extreme phenotype cells: the anti-tumour M1 cells and the
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pro-tumour M2 cells. The dynamics of the tumour-immune interactions is de-
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This model incorporates the following assumptions:
– In equation (1a) we assume that the tumour cells proliferate at a base-
line rate pt, following a logistic growth law with carrying capacity KT , to
account for a slow-down in growth at larger sizes due to a lack of nutri-
ents [37]. Tumour proliferation rate is increased (at a rate rm) by the pres-
ence of M2-like macrophages, which were shown in [69] to contribute to the
growth of breast cancer cells following their co-culture. Finally, the tumour
cells can be eliminated at a rate dt by the anti-tumour M1-like macrophages
(via antibody-dependent cell phagocytosis [29]). Since tumour cells are
usually long-lived (with limitless replicative potential and evasion of pro-
grammed cell death being two of the hallmarks of cancers [30]), in this
study we decided to ignore the death rate of cancer cells. This makes sense
in the context of 4T1 cells that can spontaneously metastasise [58], despite
the fact that in general tumour cell survival is a rate-limiting step in cancer
metastasis [68].
– The M1 macrophages in equation (1b) are recruited and proliferate at a
rate pm1, up to a carrying capacity KM . This assumption of logistic growth
is made to describe the typical experimental growth curves of macrophages,
which show an exponential phase followed by a stationary phase; see [10].
In addition, the assumption that the logistic term describes both recruit-
ment and proliferation is made since it is currently not clear if all tumour-
associated macrophages are derived from blood monocytes recruited to the
tissue, or derived from embryonic macrophages that locally proliferate in
the tissue, or both [70]. Also, having only one term that describes both
recruitment and proliferation allows us to avoid introducing another pa-
rameter into the model.
Returning to the description of terms in equation (1b), we assume that
the M1 macrophages can die at a rate dm. They can re-polarise at a
rate αm1 into M2 cells in response to signalling molecules, such as IL10,
TGF-β, that are secreted by the tumour cells [62]. To avoid an unreal-
istically large M1→M2 re-polarisation in the presence of large tumours,
we used a saturated term with K∗T a constant for the level of tumour
cells (or cytokines/chemokines produced by these cells) that trigger this
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re-polarisation. We also assume that the M2 cells can re-polarise into M1
cells at a smaller rate αm2 in the presence of molecules such as IFN-γ se-
creted by other anti-tumour cells in the environment, e.g., NK cells, CD8+
T cells [23]. This M2→M1 re-polarisation could also be induced externally
with the aim of reducing tumour progression [25].
– The M2 macrophages can proliferate in a logistic manner at a rate pm2.
For simplicity, throughout this study we assume that pm1 = pm2 =: pm.
Again, for simplicity (and because we do not have any data to support
other assumptions), we assume that the M2 cells have a similar half-life
as the M1 cells (and therefore they die at a rate dm). The re-polarisation
rates have been discussed above.
2.2 Continuous phenotype macrophage population
Consider now the following coupled ODE-PDE model for the dynamics of tu-
mour cells, uT (t), and a phenotype-structured macrophage population uM (m, t),























γ(t)uMF (uT , uM )
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= pmuM (m, t)
(
1− uM (m, t)
KM
)
− dmuM (m, t),
(2b)
with the re-polarisation function F (uT , uM ) defined as






H2(m)uM (m, t)dm, (3)
where the first term models the re-polarisation (at rate αm1) of uM cells to-
wards a M2-like phenotype in the presence of uT cells, while the second term
models the re-polarisation (at rate αm2) of uM cells towards a M1-like phe-
notype. The re-polarisation speed γ(t) is defined as a decreasing function of
the M2-like macrophages, to model the situation where once the macrophages
acquired the M2 phenotype (i.e.,
∫ Lm
0
H2(m)uM (m, t)dm is large), the move-





Here, g0 is a slow-down index for macrophages’ progression through the phe-
notype space. This slow-down index models the assumption that while initially
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macrophages re-polarise quickly away from them = 0 phenotype (under the in-
fluence of tumour cells), this re-polarisation slows down after the cells acquire
a mixed phenotype. This assumption is supported by experimental studies
that emphasise the fast acquisition of mixed phenotypes by many tumour-
associated macrophages; for example, in [35] the authors have seen that after
72hr of differentiation, more than 90% of macrophages had a mixed phenotype
polarisation. Of course, if the immune cells have mostly a M1-like phenotype,
then γ(t) ≈ 1 and the speed of M1→M2 re-polarisation will be determined by
αm1.
The right-hand-side of equation (2b) for macrophages was obtained by
adding the two ODEs (1b) and (1c) for the extreme M1 and M2 phenotypes
(and therefore it incorporates similar assumptions as for model (1)). Note that
the logistic growth is assumed to depend only on the macrophage population
with the same phenotype m. This is because the M1-like cells lead to the pro-
duction of type-1 cytokines (e.g., IFN-γ secreted by Th1 CD4+ T cells [55])
that can trigger the further differentiation and growth of M1-like cell popula-
tion [1,6], while the M2-like cells lead to the production of type-2 cytokines
(e.g., IL-4 secreted by Th2 CD4+ T cells [55]) that can trigger the further dif-
ferentiation and growth of M2-like cell population [1]. The two kernels H1(m)
and H2(m) that appear on the right-hand-side of equation (2a) describe the
phenotype ranges that characterise the M1 and M2 cells. Throughout this
study we will consider two cases (although we discuss the impact of different
types of kernels in Appendix D):
– There is a distinct separation between the phenotypes of cells considered
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(5)
– There is an overlap between the phenotypes of cells considered to be M1





, for 0 ≤ m ≤ Lm2 + ε
0, for m > Lm2 + ε
and H2(m) =
{
0, for 0 ≤ m ≤ Lm2 − ε
2
Lm+2ε
, for m > Lm2 − ε
(6)
Here, ε gives the degree of overlap between the phenotype kernels H1 and
H2: for ε = 0, equations (6) reduce to (5).
In the following we investigate the behaviour of models (1) and (2), by
starting in Section 3.1 with the asymptotic dynamics described by the steady
states, under the assumption that the system approaches a “quasi-equilibria”,
where the tumour and macrophage populations don’t vary much. Then, we















Fig. 3 (a) Distinct step-wise kernels (5) defined on two distinct intervals over the phenotype
domain: [0, Lm/2] and [Lm/2, Lm], where we consider an arbitrary phenotype domain length
Lm = 10. (b) Overlapping step-wise kernels (6), which have similar values in the middle of
the phenotype domain over the range of [Lm/2− ε, Lm/2 + ε].
systems, as given by the numerical simulations. The parameter values used for
these results are summarised in Table 1 in Appendix A.
3 Results
3.1 Steady states and their linear stability
To investigate the long-term dynamics of models (1) and (2), we focus on the











and their local stability.
We need to emphasise that in the context of cancer-immune interactions,
when we refer to these steady states we actually mean “quasi-steady states”.
When the tumour is present, a quasi-equilibrium means that the tumours
doesn’t change significantly its size at least for some time after it consumes the
available nutrients [36,37] (and thus it undergoes an angiogenic dormancy [17]),
or when it is controlled by the immune cells during the process of immune-
mediated dormancy [17,67]. In the absence of tumours, the quasi-equilibrium
is characterised by macrophages that perform surveillance tasks [50].
3.1.1 Extreme-phenotype case: model (1)
Model (1) can exhibit the following 5 types of steady states (whose stability
is discussed in more detail in Appendix B):




M2) = (0, 0, 0), which is always unstable (see Appendix B);







, 0), with pm > dm. This state is unstable
if ptpm > dtKM (pm − dm) (see Appendix B);




M2) = (0, u
∗
M1 > 0, u
∗
M2 > 0) which exists only when pm1 6=
pm2 (see Appendix B). This case is not considered in this study, where we
assume (for simplicity) that pm1 = pm2 = pm.
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Fig. 4 (a) Coexistence steady state (u∗T > 0, u
∗
M1 > 0, u
∗
M2 > 0) for the discrete phenotype
model (1). We show the tumour state u∗T as a function of dt as we vary (i) αm2; (ii) pm; (iii)
pt. (b) Coexistence steady state (u∗T > 0, u
∗
M > 0) for the continuous phenotype model (2).
We show the tumour state u∗T as a function of dt, while we vary (i) pm; (ii) pt. All other
parameters are fixed at their baseline values in Table 1.




M2) = (KT , 0, 0), which is unstable if pm > dm (see Appendix B);
5. (u∗T > 0, u
∗
M1 > 0, u
∗
M2 > 0) given by u
∗
M1 = KM (pm − dm)/pm − u∗M2,
and u∗M2 and u
∗
































In regard to the parameter regions where this coexistence steady state
exists, in Fig. 4(a) we graph u∗T as a function of various parameters. When
dt is small, there is always one steady state with large u
∗
T , irrespective of the
values of αm2, pt or pm (or any other model parameters). For intermediate
dt, there could be two co-existence steady states: one with a high tumour
population and one with a relatively low tumour population, which can be
considered as a dormant tumour state (being kept under control by the M1
cells). For large dt there is no co-existence state, as the tumour will always
be eliminated.
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We will return to this discussion at the end of Section 3.2.1, in the context
of numerical simulations. Moreover, for the stability of this coexistence
state, see Fig. 9 in Appendix B.
It is not possible to have a steady state formed of tumour cells and only one
macrophage phenotype (i.e., u∗M2 > 0 & u
∗
M1 = 0; or u
∗
M2 = 0 & u
∗
M1 > 0). In
the presence of the tumour, there must always be some level of M1 and M2
cells in the system. This result is consistent with the experimental observation
that solid tumours contain macrophages with mixed M1/M2 phenotypes [45].
A less realistic steady state is the tumour-only state. To ensure that this state
is never reached, in this study we focus only on those pm and dm values such
that pm > dm.
3.1.2 Continuous phenotype case: model (2)
In regard to the phenotypic-homogeneous steady states uT (t) = u
∗
T , uM (m, t) =
u∗M = const., it can be easily shown that model (2) exhibits the same steady
states as model (1) after we add the M1 and M2 populations:
1. (u∗T , u
∗
M ) = (0, 0), which is always unstable (see Appendix C);
2. (u∗T , u
∗
M ) = (0,KM
pm−dm
pm
), which is asymptotically stable provided that
pmpt < dtKM (pm − dm)− ptrmKM (pm − dm) (see Appendix C);
3. (u∗T , u
∗
M ) = (KT , 0), which is asymptotically unstable when pm > dm (for
all phenotypic wavenumbers; see Appendix C);
4. (u∗T , u
∗
M ) given explicitly by
u∗M = KM (pm − dm)/pm, and (8a)









This state, which exists for pm > dm and ptpm+KM (ptrm−dt)(pm−dm) >
0, is always asymptotically stable (for all phenotypic wavenumbers; see
Appendix C). Note that the condition for the existence of this state is the
same as the instability condition for the state (0, u∗M > 0). In Fig. 4(b)
we graph u∗T as a function of dt for different values of pt and pm (which
influence the existence of this state).
Remark 1 To describe the asymptotic dynamics of model (2), one needs to
calculate the phenotypically-heterogeneous steady states (u∗T , u
∗
M (m)), which
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and
F (u∗T , u
∗











These states could be further simplified if we assume that there is no tumour
(i.e., u∗T = 0; see also the simulations in Section 3.2.2). However, a closed-
form phenotypically-heterogeneous solution is difficult to obtain even in this
case due to the integral terms in F (0, u∗M ), and thus a numerical approach
has to be considered when calculating these states. Fig. 5 shows an example
of a phenotypically-heterogeneous state, which corresponds to the asymptotic





































phenotype (m) phenotype (m)
Fig. 5 Time snapshot of a state with no tumour (u∗T ) and a phenotypically-heterogeneous
macrophage population (u∗M (m)). The simulations were obtained with model (2), for the
parameter values listed in the caption of Fig. 7(c’).
3.2 Numerical results
In the following, we focus on the transient behaviour of models (1) and (2), and
investigate the effect of various parameters on tumour growth/decay. As initial
conditions for the ODE model (1) we choose uT (0) = 0.05, uM1(0) = 0.001,
uM2(0) = 0.00037. To propagate the solution at the next time step, we use a
classical Runge-Kutta finite difference discretisation method.
Regarding the structured-population model (2), we assume that a small
number of cells are introduced into the environment at t = 0, uT (0) = 0.05
(same as for the discrete-phenotype case), which leads to the activation and
recruitment of macrophages with a dominant M1 phenotype (i.e., the peak of
the uM (m) distribution is closer to m = 0 than to m = Lm):
uM (m, 0) = 0.03e
−15(m−Lm/10)2 , with Lm = 10. (9)




uM (m, 0)dm = uM1(0) + uM2(0). To simulate numerically the
solution of (2), we first discretise the integrals using Simpson’s method. Then
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we use an operator-splitting approach to deal with the advection term describ-
ing the transport through the phenotype m-space (which is discretised using
a second-order MacCormack finite difference scheme), and with the reaction
term describing cells proliferation/death (which is discretised using again a 4th
order Runge-Kutta scheme). Finally, since we work on a bounded phenotype
domain, we use no-flux boundary conditions.
In the following two subsections we investigate numerically the effects of
two model parameters that are usually varied through immunotherapies, but
are still not fully understood:
– The tumour-killing rate dt, which might vary since it depends, for example,
on the amount of membrane M-CSF present on the target tumour cells [33],
or the PD-1 expression of tumour-associated macrophages which inhibits
phagocytosis [27]. However, as emphasised in [48], the detailed mechanisms
of tumour cell phagocytosis are not completely understood at this moment.
– The M2→M1 re-polarisation rate αm2, which has been investigated experi-
mentally and clinically over the past few years, with numerous macrophage
re-polarising molecules being identified [12]. However, many of these re-
polarising molecules are not able to generate durable tumouricidal ef-
fects [12]. Examples of molecules that have been show to lead to anti-
tumour activities are microRNA-155 [7], acidic polysaccharides [38], or
GM-CSF [18].
3.2.1 Numerical simulation of the discrete-phenotype model
Given that many experimental studies focus on methods to re-program tumour-
associated macrophages towards an anti-tumour phenotype [12,21,24], in Fig. 6
we investigate the interplay between αm2 (the M2→M1 re-polarisation rate)
and dt (the killing rate of tumour cells by M1-like macrophages). Since vari-
ous experimental studies discuss tumour progression in terms of the ratio of
M1/M2 cells infiltrating solid tumours as well as the total numbers of infiltrat-
ing macrophages [9,31,42,56], in sub-panels (ii) we graph the percentage of M1
and M2 cells in the tumour environment (on the left vertical axis), and their
total numbers/densities (on the right vertical axis). We emphasise that tumour
growth can occur in the presence of a large number of M2 cells (Fig. 6(a)(i)),
or large numbers of M1 cells (Fig. 6(b)(i)). Increasing the re-polarisation rate
αm2 (Figs. 6(b)(i) and (d)(i)), to simulate the effect of tumour-associated
macrophages’ re-polarisation towards M1-like cells, does not automatically
lead to tumour elimination if the macrophages had deficient phagocytosis de-
scribed by low dt. Increasing the rate dt leads to tumour control (even when
uM2 > uM1; panel (c)), or even tumour elimination (when uM1 > uM2 and
dt > 1). Note that tumour elimination occurs when the system approaches
the steady state (0, u∗M1, 0), as the tumour-present state ceases to exist (see
Fig. 4(a)), thus pushing the system towards the stable tumour-free state.
In the following we investigate numerically the case of a continuous phe-
notype space, where we can understand better the anti-tumour/pro-tumour ef-
fects of macrophages with mixed phenotypes, as described by model (2)+(5)+(6).
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t=5      t=10     t=20     t=40
t=5     t=10     t=20     t=40  
Fig. 6 Short-term dynamics of model (1), as we vary αm2 and dt. Sub-panels (i) show the
time-evolution of uT , uM1 and uM2, while sub-panels (ii) show the percentages of M1 and
M2 cells on the primary (left) vertical axis, and the total number of macrophages on the
secondary (right) vertical axis.
3.2.2 Numerical simulations of the continuous-phenotype model
To investigate the pro-tumour/anti-tumour effects of macrophages with dis-
tinct or mixed phenotypes, we focus on the two types of phenotype kernels
described in Fig. 3, as we vary dt and αm2.
– Step-wise kernels (5) for distinct M1-M2 phenotype separation. In Fig. 7(a)-
(c) we show the dynamics of model (2) as we assume that αm1  αm2 and
vary the rate dt. For a small dt (see Fig. 7(a)) tumour grows towards its
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carrying capacity, being helped by the macrophages which evolve towards
an M2-like phenotype (i.e., m > Lm/2 = 5). As we increase dt we see first a
temporary reduction in tumour size (Fig. 7(b)), and eventually a complete
tumour elimination (Fig. 7(c)) characterised by M1-like macrophages in the
tumour microenvironment. Note that this M1-like phenotype is induced by
the shrinking tumour (as αm1  αm2).
In Fig. 7(a’)-(c’) we increase the re-polarisation rate αm2 such that αm2 
αm1, and we observe that a high αm2 combined with a low dt slows down
the M1→M2 re-polarisation, but it cannot control tumour growth (sub-
panels (a’)). Combining a large αm2 with a large dt (sub-panels (b’),(c’))
induces a shift in the macrophage phenotype, which leads to tumour elim-
ination. This also leads to an accumulation of macrophages at the left
boundary (due to the no-flux boundary conditions), and thus the system
approaches a tumour-free heterogeneous-phenotype macrophage state, as
in Fig. 5. Tumour elimination is associated with the disappearance of the
tumour-present/macrophage-present state (8) caused by large dt (which
also induces a change in the stability of this coexistence state; see Ap-
pendix C). The very high levels of dt required to control/eliminate the
tumour (compared to the discrete-phenotype case) are the results of low
total macrophage density (i.e., u∗M ≈ 20%u∗T ).
– Step-wise kernels (6) with phenotype overlap. We assume that there is no
perfect delimitation between the M1 and M2 cells (or actually, their anti-
tumour/pro-tumour effects, in the sense that even the M1-like cells could
carry some M2 markers). In Fig. 8 we graph the dynamics of model (2)
under the assumption that αm1  αm2, and dt = 2. It is clear that in-
creasing the phenotype overlap leads to a delay in tumour reduction (but
a greater reduction), as well as a delay in tumour relapse.
4 Summary and Discussion
While there are many mathematical studies in the literature that focus on
the two extreme macrophage phenotypes, M1 and M2, our study is one of
the very few that focus on both discrete and continuous phenotypes. Here, we
introduced two simple models for tumour-macrophage interactions, where we
considered: (i) a macrophage population with two extreme phenotypes (M1
and M2) which could re-polarise in response to tumour-secreted cytokines
or growth factors, or in response to external actions, and (ii) a phenotype-
structured macrophage population. We used these models to investigate the
mechanisms involved in tumour growth/control/elimination, as well as the
importance of considering discrete vs. continuous macrophages phenotypes in
tumour progression.
We first compared the models in terms of the steady states they exhibit,
and showed that while the re-polarisation rates α1 and α2 impact the type
and stability of the steady states for the model with discrete phenotypes,
they do not have any significant effect on the states exhibited by the model
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(a) d  =0.1t (b) d  =2.0
Fig. 7 Dynamics of system (2) with phenotype kernels (5) when: (a)-(c) we fix αm1 =
0.1  αm2 = 0.01 and vary dt, and (a’)-(c’) we fix αm1 = 0.1  αm2 = 0.5 and vary dt:
(a),(a’) dt = 0.1, (b),(b’) dt = 2.0, (c),(c’) dt = 4.0. Sub-panels (i) show the total tumour
density uT (t) and total macrophages density: uM (t) =
∫ Lm
0 uM (m, t)dm; sub-panels (iii)
show the evolution of macrophages density in the (m, t) space. Dotted vertical line in sub-
panels (iii) show the threshold phenotype m = Lm
2
= 5, which separates the anti-tumour
(M1) macrophages from the pro-tumour (M2) macrophages. Parameter values are: pt = 0.6,
pm = 0.7, dm = 0.23, KM = KT = 1.0, K
∗
T = 0.01, rm = 0.1, g0 = 1.5.
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H (m)2H (m)1
Kernels (6): Kernels (6): Kernels (6):(a) (b) (c)
H (m)
phenotype (m)phenotype (m) phenotype (m)
(i)(i) (i)
(ii)
Fig. 8 Dynamics of system (2) with phenotype kernels (6), as we vary the overlap between
M1 and M2 phenotypes of macrophages: from (a) ε = 0.01, to (b) ε = 1.0 and (c) ε = 2.0.
Sub-panels (i) show the kernels H1,2(m) for different ε; sub-panels (ii) show the total tumour
and macrophages density; sub-panels (iii) show the phenotype distribution of macrophages
during the evolution of tumour cells.
with continuous phenotype (because in this case, the re-polarisation rates were
assumed to impact the movement through the phenotype space, and therefore
they appeared only in the heterogeneous-phenotype steady states). Moreover,
for the discrete-phenotype case we also showed that it was possible to have
multiple tumour-macrophages coexistence states: with high tumour densities
and low tumour densities; see Fig. 4(a). The low tumour branches correspond
to the case of immune-mediated tumour dormancy, as the M1 cells controlled
the growth of the tumour. The existence of these multiple co-existent states
for the discrete-phenotype case was in contrast with the continuous-phenotype
case where there was only one tumour-macrophage co-existence steady state;
see Fig. 4(b). It should be emphasised here that the shape of the phenotype
kernel did not have any impact on the type or stability of the phenotype-
homogeneous steady states displayed by model (2); see also the discussion in
Appendix C.
The numerical simulations for the discrete phenotype and continuous phe-
notype (with distinct kernels) showed relatively similar dynamics: tumour
growth towards maximum size, temporary tumour control, or tumour elim-
ination. Tumour elimination was the result of the disappearance of the coexis-
tence state, which for the continuous phenotype model coincided also with the
loss of stability of this state. (For the coexistence steady states with discrete
phenotypes it was difficult to obtain an analytical condition for the loss of their
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stability, to connect it with the analytical condition for the existence of these
states.) For the models introduced in this study, a M2→M1 re-polarisation
– which is one of the methods currently used in experiments to promote
tumour regression [12,24] – could not lead to tumour elimination unless it
was accompanied by an increase in the phagocytosis rate of tumour cells by
macrophages (i.e., an increase in dt, which can be obtained experimentally, for
example, via monoclonal antibodies [29] or via an inhibition of PD-1 expres-
sion by tumour-associated macrophages [27]). This suggests that a combined
therapeutic approach involving both a M2→M1 re-polarisation as well as an
increase in phagocytosis might improve the current therapeutic outcomes.
The continuous phenotype model also showed tumour dormant behaviours,
which occurred for large macrophage phagocytosis rates (dt) in the context of
mixed macrophages phenotypes; see Fig. 7(b’). In this case, for the param-
eter values considered in this study (see Table 1) the tumour was always
eliminated as the M1-like phenotype won over the M2-like phenotype. Our
theoretical study hypothesises that this immune-mediated dormancy is asso-
ciated with the evolution of macrophage phenotype from an initial M1-like
phenotype to a mixed M1/M2 phenotype. This aspect will have to be inves-
tigated experimentally since at this moment there are very few studies in the
literature that focus on the phenotype of TAMs during tumour dormancy.
Among these few experimental studies we mention [69], which suggests that
the M1 macrophages may contribute to dormancy behaviours in metastatic
breast cancer cells. However, in [69] it is not investigated whether those M1
macrophages could have also mixed phenotypes.
By focusing our attention on the amount of overlap between M1 and M2
markers, described in the model by the overlap between the kernels H1(m)
and H2(m), we showed that a larger markers’ overlap can lead to a delay in
the reduction of tumours, as well as a delay in tumour relapse; see Fig. 8.
Unfortunately, few experimental studies quantify the number/percentage of
tumour-associated macrophages with mixed phenotypes; see [3,60]. If such
experimental studies will be performed more often in the future, they could be
used to inform the choice of phenotype kernels. This is particularly important
since the simulations in Figs. 7-8 and Fig. 11 in Appendix D showed that
the type of phenotype kernel can influence the rate at which the tumour is
eliminated or grows back.
We need to emphasise that the models introduced in this study are very
simple. For example, we assumed that the M1 and M2 proliferation rates
could be described by an average value pm, and their death rates could be
described by an average value dm. (This assumption allowed us to go from
model (1) to model (2).) In the absence of any data to suggest otherwise, this
was an acceptable assumption. However, given the different phenotypes and
functions of the tumour-associated macrophages, it also raises the question of
whether the proliferation/death rates could depend on the phenotype. More
experiments need to be performed on macrophages turnover, before we clarify
this aspect.
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More complex tumour-macrophage interactions, and interactions between
macrophages and other immune cells in the tumour microenvironment, e.g.,
CD4+ or CD8+ T cells, will be considered in future studies. Also, multiscale
approaches will be developed to connect this cell-scale model with molec-
ular dynamics that will help us understand better the functionality of M1
macrophages.
Acknowledgements R.E. acknowledges useful comments made by the reviewers, who
helped improve this manuscript.
A Parameter values
Table 1 summarises the values of the parameters used throughout this study to simulate
the dynamics of model (1). For simplicity, we have re-scaled the cell populations by their
carrying capacities. This leads also to a re-scaling of the following parameters: r̃m = rmKM ,





. Now K̃∗T , K̃T , K̃M , and rm are dimensionless,
while d̃t has units of 1/time. All other parameters kept their original units. For simplicity,
in Table 1 we ignore the tilde symbol˜for the rescaled parameters, but specify in the third
column the units for these parameters (as well as the units for the unscaled parameters).
Regarding the parameters that kept their units, we made the following assumptions:
– We focus on breast cancer, and use the information from [28,53,72] to approximate pt.
Note that in [53], five different breast cancer cell lines were derived from one cancer
patient (with stage I invasive ductal carcinoma), and then injected into BALB/c mice.
The doubling times for all these clones were between 24− 36 hours [53], which implies








breast cancer cell lines (also injected in BALB/c mice) have different doubling times,
which can vary greatly between experiments. For example, the doubling time of 4T1
breast cancer cells (usually used to study stage IV human breast cancer) was shown
to vary from 14.7 − 15 hours (i.e., pt ≈ 1.1/day) in [72] to more than 4.3 days (i.e.,
pt ≈ 0.16) in [28]. Therefore, in this study we consider an average tumour proliferation
rate pt = 0.6/day.
– Unlike the tissue-resident macrophages that can persist for weeks and even months [26,
61], the tumour-associated macrophages have a very rapid turnover of less than 5 days
[54,65]. In this study, we consider a TAM half-life of 3 days, corresponding to a death
rate dm1 = dm2 = dm ≈ 0.23/day.
– Regarding macrophage proliferation, in [10] the authors observed that primary bone
marrow derived macrophages have a doubling time of 20 hrs, while the splenocyte derived
macrophages have a doubling time of 30 hrs. This translates into a proliferation rate
pm ∈ (ln(2.0)/30hr, ln(2.0)/20hr) ≈ (0.55, 0.83)/day. For the numerical simulations we
consider an averaged rate pm = 0.7/day.
In regard to the dimensional (and non-dimensional) values value of KT and K
∗
T , note that
in [22] the authors suggested that the tumour diagnostic level is between 107 − 109 cells.
In mice, tumours are considered lethal if they are larger than 1cm3, which corresponds
to a maximum of ≈ 109 cells [13,51]. Thus, we can assume that the dimensional carrying
capacity for a murine tumour is KT = 10
9. Since at diagnostic (i.e. ≈ 107 cells) the tumours
are already infiltrated with macrophages, we assume that the maximum tumour level that
triggers a M1→M1 polarisation is K∗T = 10
7 = 1%KT . Following the re-scaling of cell
populations by their carrying capacities, we obtained the non-dimensional values KT and
K∗T shown in Table 1 (see also the discussion about the re-scaled cell populations, at the
beginning of this Appendix A).
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Table 1 Summary of parameters used for model (1). Since many parameters were varied
over some ranges, in parentheses we show the baseline values used throughout this study.
We chose these baseline values to describe tumour growth towards carrying capacity, so that













Proliferation rate of tumour cells [53,72,28]
KT 1 - Carrying capacity of tumour cells
K∗T 0.01 - Tumour level that triggers a M1→M2
macrophages re-polarisation
rm 0.1 - Contribution of M2 macrophages to the prolif-











Proliferation rate of M1 and M2 macrophages
[10]

















Re-polarisation rate of M1 macrophages to-
wards the M2-phenotype
Lm 10 space Length of the phenotype domain
g0 1.5 - Slow-down index for movement though the
phenotype space
B Stability of steady states for model (1)























































































































− dm − αm2

Proposition 1 Consider model (1) with the two extreme macrophage phenotypes, which
can exhibit three steady states with neither macrophages nor tumour cells, or with only
macrophages, or with only tumour cells.
1. The tumour-free macrophages-free steady state (0, 0, 0) is always unstable.
2. The tumour-free M2-present steady state (0,
(pm−dm)KM
pm
, 0), which exists only for
pm > dm, is asymptotically stable if and only if pmpt < dtKM (pm − dm).
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3. The tumour-present macrophages-free steady state (KT , 0, 0) is asymptotically stable if
and only if pm < dm.
Proof:
1. The eigenvalues of the Jacobian matrix at the steady state (0, 0, 0) are λ1 = pt > 0,
λ2 = pm − dm, and λ3 = pm − dm − αm2. Since λ1 > 0, this steady state is always
unstable.
2. The eigenvalues of the Jacobian matrix at the steady state (0,
(pm−dm)KM
pm
, 0) are λ1 =
−(pm − dm) < 0, λ2 = −αm2 < 0 and
λ3 =
−dtKM (pm − dm) + ptpm
pm
.
Therefore, the steady state (0,
(pm−dm)KM
pm
, 0) is asymptotically stable if λ3 < 0 and
unstable if λ3 > 0.
3. The eigenvalues of the Jacobian matrix at the steady state (KT , 0, 0) are λ1 = −pt < 0,
λ2 = −(dm − pm), and
λ3 = −
KT (αm1 + αm2) + (KT +K
∗





Since for dm > pm all eigenvalues are negative, the steady state (KT , 0, 0) is asymptot-
ically stable. The state is unstable when pm > dm.





is more difficult to be studied analytically in terms of all model parameters. Of course, we
could simplify a bit the determinant |J − λI| = 0 (e.g., by adding 3rd row to the 2nd row,

















































which leads to one obvious eigenvalue λ1 = −(pm−dm). However, the other two eigenvalues
are the roots of the quadratic equation:







































































By looking at the above inequality, one could say that this inequality cannot hold for αm2
large. However, given that u∗T depends on model parameters and implicitly on αm2 (through
equations (7)), it is difficult to obtain a clear understanding of the stability of this coex-
istence state in terms of various model parameters (and whether stability correlates with
the existence of this state – as we will see in Appendix C for model (2)). However, we
can fix model parameters (e.g., to the values in Table 1) and find these steady states and
their stability. In this context, we note that the tumour-present macrophage-present state
is stable for the baseline parameter values in Table 1. Hence, it expected that the baseline
numerical simulations will approach this state; see also Fig. 6(a)(i).
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1 stable steady state (s.s)



































Fig. 9 Stability of the tumour-present/macrophage-present steady states (7) – when they
exists – in the parameter space (dt, αm2). Here αm1 = 0.1 and all other parameter values
are as is Table 1. When only 1 steady state (s.s.) exists, it is always stable (−); when 2
steady states co-exists, one is stable (−) and the other one is unstable (+).
Remark 3 As mentioned in the main text, the steady state (0,M∗1 > 0,M
∗
2 > 0) exists






pm2 − (dm + αm2)
]





(αm2 + dm)(pm2 − pm1)− αm2pm2
][
pm2 − (dm + αm2)
]
pm2(αm2 + dm)(pm2 − pm1)
.
Note that both u∗M1 > 0 and u
∗
M2 > 0 exist only if pm2 > max{pm1, dm + αm2}.
The case pm1 = pm2 = pm reduces the steady-state equations (1b)-(1c) to the following
expression (since 1− (u∗M1 + u
∗
M2)/KM = (αm2 + dm)/pm2, and thus u
∗
M1 will disappear
from the steady-state equation (1b)):
0 = αm2KM
[
pm2 − (dm + αm2)
]
⇔ pm2 = dm + αm2.
However, substituting the above right-hand-side expression into
u∗M2 =
[





leads to u∗M2 = −u
∗





cannot exist when pm1 = pm2 = pm.
Since in this study we considered only the case pm1 = pm2 =: pm (for simplicity, and to
connect the results of the discrete-phenotype model (1) and the continuous-phenotype model
(2); see Figs. 4(a) vs. 4(b)), here we chose to not discuss the stability of the tumour-free
macrophages-present steady state.
C Stability of steady states for model (2)
We now consider small perturbations of the phenotypically-homogeneous steady states u∗T
and u∗M (i.e., uT (t) = u
∗
T + a1e







































































σ1 = −B11, σ2 = −B22.
First note that the kernels H1(m) and H2(m) (which appear only in B12) do not influence
these roots, and so the shape of the kernels (see Fig. 3) does not have any impact on the
stability of the phenotype-homogeneous steady states. Second, note that the wavenumber
k appears only in σ2 = −B22, and it does so in the complex part of this root. Hence, the
steady states will be stable/unstable to an infinite range of wavenumbers.
Proposition 2 Consider model (2) with the continuous macrophage phenotype, which can
exhibit four phenotype-heterogeneous steady states.
1. The tumour-free macrophage-free steady state (u∗T , u
∗
M ) = (0, 0) is always unstable.
2. The tumour-free macrophage-present steady state (u∗T , u
∗




totically stable if and only if pmpt < dtKM (pm − dm)− ptrmKM (pm − dm).
3. The tumour-present macrophage-free steady state (u∗T , u
∗
M ) = (KT , 0) is unstable if
pm > dm.
4. The tumour-present macrophage-present steady state (u∗T > 0, u
∗
M > 0) is always
asymptotically stable.
Before discussing briefly how these stability results were obtained, note that the inequality
for the stability of the tumour-free macrophage-present state is more restrictive than the
inequality for the stability of the discrete-phenotype steady state (0, (pm− dm)KM/pm, 0).
This is explained by the difference in the steady states: the phenotypically-discrete states





and thus they can be de-stabilised by increasing the M2 sub-population.
Proof:
1. At the trivial state (0, 0), the roots of the characteristic equation are σ1 = pt > 0 and
σ2 = (pm − dm), and therefore this state is always unstable .
2. At the state (0,
(pm−dm)KM
pm
), which exists only if pm > dm, the roots of the charac-
teristic equation are








and therefore the steady state is asymptotically stable when σ1 < 0, which leads to the
required inequality.
3. At the state (KT , 0), the roots of the characteristic equation are σ1 = −pt < 0 and
Re(σ2(k)) = pm − dm > 0, and thus this state is always unstable.
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4. At the steady state (u∗T > 0, u
∗
M > 0), which exists only for (pm − dm) > 0 and
dt − ptrm < pmpt(pm−dm)KM , we have Re(σ2(k)) = −(pm − dm) < 0. Thus the stability is
controlled by σ1:
σ1 =
(−ptrm + dt)(pm − dm)KM − pmpt
pm




This last inequality coincides with the inequality for the existence of this state (see
equation (8b)), and thus the state is asymptotically stable whenever it exists.
Fig. 10 shows the real and imaginary parts of σ1 and σ2 for wavenumber k < 100 and
dt = 0.5 (continuous lines) and dt = 1.0 (dash-dot lines). As discussed above, increasing dt
can lead to unstable states; however this instability is characterised by an infinite number
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Fig. 10 Dispersion relation σ1,2(k), corresponding to the phenotypically-homogeneous
steady state (u∗T > 0, u
∗
M > 0) given by equations (8), as we vary the rate dt at which
M1-like macrophages eliminate the tumour cells.
D The impact of different shapes of phenotype kernels
We have seen in Fig. 8 that an overlap in the macrophages phenotype leads to a delay in
the killing and relapse of tumour cells. There, we considered phenotype kernels that put
similar emphasis on cells with M1 and M2 phenotypes. Here we investigate what happens
if we change the shape of the phenotype kernel, and put more emphasis on the cells with
more extreme phenotypes (e.g., on the M1 macrophages with a phenotype m < 3, and on
the M2 macrophages with a phenotype m > 7). In Fig. 11(i) we depict two such types of
kernels:
(i) H1(m) = me











1+ε , with ε = 0.3. (14b)
Comparing Fig 11(ii) with Fig. 7(b)(i), we see that the shape of the kernels does have an
impact on the level of tumour reduction by the M1 cells (when we keep all other model
parameters and initial conditions fixed). In particular, kernels (14) lead to a much smaller
reduction in tumour population compared to kernels (5)-(6).
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Fig. 11 Dynamics of system (2) with: (a) kernels (14a), and (b) kernels (14b), as we vary
the degree of overlap between H1 and H2. Here, pm = 0.7, pt = 0.6, αm1 = 0.1, αm2 = 0.01,
dt = 2.0, and the rest of the parameters are as in Table 1.
Various other types of kernels, with or without overlap, could be used to model macrophages
phenotype. An extreme type of such kernel without overlap can be described by a delta func-
tion, which would allow us to reduce the non-local terms for continuous phenotype to local
terms describing the interactions between the discrete M1 and M2 phenotypes, and thus
compare models (1) and (2). However, since the goal of this study is not to focus on more
models with discrete phenotype, but rather to investigate the impact of M1/M2 mixed
phenotype on tumour outcomes, we leave such a comparison for a future study.
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